Physician profile
Amanda Helms
NPI 1649993411
$1,867.12
in general payments reported to CMS, 2019-2025
9 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $248 · 2023: $800 · 2024: $703 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $688.69 | 2022-2025 | Jardiance |
| Novo Nordisk INC | $407.55 | 2022-2024 | Wegovy, Ozempic |
| Merck Sharp & Dohme LLC | $404.85 | 2022-2025 | Verquvo, Belsomra, Steglatro |
| Daiichi Sankyo INC. | $159.34 | 2022-2024 | Injectafer |
| Olympus America INC. | $71.46 | 2023-2025 | Bovie, Soltive, Soltive |
| Angiodynamics, INC. | $49.95 | 2023 | Venacure 1470 Pro |
| Astellas Pharma US INC | $39.45 | 2024-2025 | Veozah, Padcev |
| Lilly USA, LLC | $30.53 | 2024 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $15.30 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Helms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.